Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan brukes som monoterapi eller i kombinasjon med metotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - raloksifenhydroklorid - osteoporose, postmenopausale - sex hormoner og modulatorer av genital systemet, - optruma er indisert for behandling og forebygging av osteoporose hos postmenopausal kvinner. en signifikant reduksjon i forekomsten av vertebrale, men ikke hoftefrakturer har blitt påvist. når valget av optruma eller andre behandlinger, inkludert østrogen, for en individuell postmenopausale kvinne, vurdering bør gis til menopausal symptomer, effekter på livmor og bryst vev, og kardiovaskulær risiko og fordeler (se del 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulin glargin - sukkersyke - legemidler som brukes i diabetes - behandling av diabetes mellitus hos voksne, ungdom og barn i alderen 2 år og eldre.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulin lispro - sukkersyke - legemidler som brukes i diabetes - for behandling av voksne og barn med diabetes mellitus som krever insulin for vedlikehold av normal glukose homeostase. humalog er også indikert for den første stabiliseringen av diabetes mellitus.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - diabetes mellitus, type 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for resultatene fra denne undersøkelsen med hensyn til kombinasjoner, effekter på glykemisk kontroll og kardiovaskulære hendelser, og bestandene studert, se kapittel 4. 4, 4. 5 og 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - bryst neoplasms - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - glucagon - sukkersyke - bukspyttkjertelen hormoner, hormoner glycogenolytic - baqsimi er angitt for behandling av alvorlig hypoglykemi hos voksne, ungdom og barn i alderen 4 år og over med diabetes mellitus.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, type 2 - legemidler som brukes i diabetes - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 og 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - kolitt, ulcerativ - immunsuppressive - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.